#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Fusarium infection Cardiac amyloidosis Palmoplantar pustulosis Juvenile chronic myelomonocytic leukaemia Muscular dystrophy Diabetes insipidus Hypotransferrinaemia Waldenstrom's macroglobulinaemia recurrent Glomerulonephritis chronic Hydrocephalus Spinal cord injury Mucous membrane pemphigoid Pyoderma gangrenosum Transplant rejection Facioscapulohumeral muscular dystrophy More trials…

    Learn about Rare Diseases

    Optic glioma – Treatment Uterine leiomyosarcoma – Trials in Disease Alagille syndrome – Diagnostics Rhabdoid tumour Cholangitis sclerosing – Life with Disease Advanced systemic mastocytosis – Trials in Disease Pulmonary sarcoidosis – Diagnostics Chordoma – Treatment IgA nephropathy Glomerulonephritis rapidly progressive – Basic Information More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Alemtuzumab Fianlimab Carmustine Milrinone Selatogrel XMAB942 Gemcitabine Hydrochloride Wt1 Mrna Dc Dazukibart SOFOSBUVIR Febuxostat Efinopegdutide Silibinin Ceftriaxone Sodium Atuliflapon GSKVX000000034792 Chloride Ion Osimertinib Colchicine Bexotegrast More therapies…

    Learn about Your Condition

    Acute myeloid leukaemia Mesothelioma Transient ischaemic attack Leiomyosarcoma metastatic Latent tuberculosis Bronchopulmonary dysplasia Cholangiosarcoma Oral lichen planus Gouty arthritis Endometriosis Peritonitis Richter's syndrome Cutaneous calcification Wiskott-Aldrich syndrome Cardiac failure chronic More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Academisch Ziekenhuis Maastricht

Academisch Ziekenhuis Maastricht

P. O. Box 616, Maastricht, 6200 MD, Netherlands

Want to learn more about this study or check if you can participate? Contact us.

  • Phase I/II Study of AZD6621 Safety and Efficacy in Adult Men with Metastatic Prostate Cancer

    Recruiting

    2 1 1
    Investigated Diseases:
    • Prostate cancer metastatic
    Belgium Italy The Netherlands Poland Spain

  • Phase II Study of Intravenous Tarlatamab for Patients with Asymptomatic Brain Metastases from Small Cell Lung Cancer

    Recruiting

    2 1 1
    Investigated Drugs:
    • Tarlatamab
    The Netherlands

  • A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Prostate cancer
    Investigated Drugs:
    • Saruparib
    • Abiraterone Acetate
    Austria Belgium Finland France Germany Hungary +5

  • Study of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

    Recruiting

    3 1 1
    Investigated Diseases:
    • Non-small cell lung cancer metastatic
    Investigated Drugs:
    • Adagrasib
    • Carboplatin
    • Cisplatin
    Austria Belgium Bulgaria Croatia France Germany +9

  • Study on Personalized Antithrombotic Therapy with Acenocoumarol, Phenprocoumon, and Apixaban for Patients with Aortic Valve Stenosis Post-TAVI

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Aortic valve stenosis
    Investigated Drugs:
    • Acenocoumarol
    • Carbasalate Calcium
    • Dabigatran Etexilate
    Belgium Denmark France Germany The Netherlands

  • Study on Dexamethasone and Fluorometholone for Patients Undergoing Corneal Transplantation

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Corneal graft failure
    • Corneal graft rejection
    Investigated Drugs:
    • Fluorometholone
    • Dexamethasone
    Germany The Netherlands

  • Study of Tarlatamab and Durvalumab compared to Durvalumab alone for patients with extensive stage small cell lung cancer

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Argipressin
    • Mannitol
    • Betamethasone Sodium Phosphate
    Austria Belgium Bulgaria Czechia Denmark France +10

  • Study of tarlatamab with durvalumab, carboplatin and etoposide versus standard treatment in patients with previously untreated extensive stage small cell lung cancer

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Small cell lung cancer extensive stage
    Investigated Drugs:
    • Etoposide
    • Carboplatin
    • Durvalumab
    Austria Belgium Denmark France Germany Greece +7

  • Study on the Safety and Effectiveness of Naronapride for Adults with Moderate Idiopathic or Diabetic Gastroparesis

    Not recruiting

    2 1
    Investigated Diseases:
    • Diabetic gastroparesis
    • Impaired gastric emptying
    Investigated Drugs:
    • Naronapride Dihydrochloride Trihydrate
    Austria Belgium France Germany Italy Latvia +2

  • Study Comparing Gilteritinib and Midostaurin with Chemotherapy for Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with FLT3 Mutation

    Not recruiting

    2 1 1 1
    Investigated Drugs:
    • Gilteritinib
    • Midostaurin
    Austria Belgium Finland France Germany Ireland +5
1 2 3
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!